The global gamma knife market size was valued at USD 424.7 million in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 5.0% from 2023 to 2030. Increasing prevalence of neurological disorders & brain tumors, rapid adoption of gamma knife surgeries as an effective treatment option, continuous technological advancements, and evolution of minimally invasive surgery options are expected to fuel the market. However, higher costs of treatments & installation of machinery, fluctuating reimbursement rates, and dearth of skilled professionals are factors expected to hamper market growth.
The COVID-19 pandemic has negatively impacted radiology practices across the globe. A 50.0% reduction in elective surgeries was witnessed within the first month of the pandemic. Hospitals are mainly focusing on tackling COVID-19 cases, which minimized their capacity to undertake critical radiotherapy operations. Reduction in raw material production, halt in logistics, reduced sales of newer systems, and national lockdowns were other reasons for the drop in market size in 2020.
The global burden of neurological disorders is measured by the absolute number of Disability-adjusted Life Years (DALYs), which continues to increase. The prevalence of major neurological disorders is increasing owing to rising geriatric population. According to American Cancer Society, brain tumor is considered as the 8th most common type of cancer and 3rd most common cause of cancer deaths in the age group of 40 & above. As population is aging and growing, the demand for treatment and rehabilitation for neurological diseases is expected to increase significantly, hence impacting the growth of the market.
Gamma knife surgery is a computer-guided treatment, which is painless and used to deliver strong focused radiation beams to treat brain tumors and lesions, arteriovenous malformations, acoustic neuroma, tremors, and trigeminal neuralgia. For instance, Leksell Gamma Knife Icon, by key market player Elekta AB (publ), uses single or fractionated frame-based or frameless treatments with more precision and accuracy for brain tumors, cancer, and other neurological diseases.
Based on indication, the market is segmented into malignant tumors, benign tumors, vascular disorders, functional disorders, and ocular brain tumors. The malignant tumors segment held the largest share in 2022 capturing 45.7% of the global industry. The benign tumors segment is expected to grow at the fastest rate over the forecast period, owing to increasing prevalence of meningioma.
According to American Society of Clinical Oncology (ASCO), currently, 700,000 patients are suffering from brain tumors. In 2021, around 24,530 adults-13,840 males and 10,690 females-in the U.S. are expected to be diagnosed with the primary type of malignant tumor in the spinal cord and brain. In addition, around 3,460 children under the age of 15 years are expected to be diagnosed with brain tumors. Around 18,600 adults-around 10,500 males and 8,100 females-are likely to die due to these types of cancer in the coming year, thereby augmenting the segment’s growth.
In 2022, Asia Pacific held the largest market with over 38.0% share. Increase in prevalence of neurological diseases, rise in healthcare expenditures, and growth in accessibility of gamma knife surgeries are some of the key factors expected to drive Asia Pacific’s gamma knife market over the forecast period.
Furthermore, the adoption of gamma knife surgery systems is reported to be increasing in North America. Moreover, various clinical studies are being undertaken for exploring the applications of gamma knife radiotherapy in treating essential tremors, such as Parkinson’s and glioblastoma. Thus, the expansion of applications of gamma knife radiotherapy to other treatment areas is expected to further drive the market.
Major participants in the market are involved in multiple strategic initiatives such as mergers & acquisitions, new product launch, collaborations and other initiatives. For instance, in May 2020, Elekta launched Leksell Gamma Knife Lightning, which was the only fully integrated automated treatment planning solution for gamma knives that enables plan-optimization based on parameters such as beam on-time constraints. Some prominent players in the global gamma knife market include:
Elekta AB
Varian Medical Systems
Huiheng Medical, Inc.
MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
Akesis Inc.
Report Attribute |
Details |
The market size value in 2023 |
USD 445.1 million |
The revenue forecast in 2030 |
USD 626.4 million |
Growth rate |
CAGR of 5.0% from 2023 to 2030 |
The base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segment Covered |
Indication, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S., Canada, UK, Germany, France, Italy, Spain, Denmark, Sweden, Norway, China, Japan, India, Australia, South Korea, Thailand, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE, Kuwait |
Key companies profiled |
Elekta AB; Varian Medical Systems; Huiheng Medical, Inc.; MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.; Akesis Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail of customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional & country levels and provides an analysis on the latest trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the gamma knife market report on the basis of indication and region:
Indication Outlook (Revenue, USD Million; 2018 - 2030)
Malignant tumors
Benign tumors
Vascular disorders
Functional disorders
Ocular diseases
Regional Outlook (Revenue, USD Million; 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
Australia
South Korea
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global gamma knife market size was estimated at USD 424.7 million in 2022 and is expected to reach USD 445.1 million in 2023.
b. The global gamma knife market is expected to grow at a compound annual growth rate of 5.0% from 2023 to 2030 to reach USD 626.4 million by 2030.
b. Asia Pacific dominated the gamma knife market with a share of 38.0% in 2022. This is attributable to a high incidence of brain tumors, and rising awareness amongst healthcare professionals regarding noninvasive treatment alternatives.
b. Some key players operating in the gamma knife market include Elekta AB, Varian Medical Systems, Cyber Medical Corporation, ET Medical Group, GE Healthcare, Masep Infini Global Inc., and Huiheng Medical, Inc.
b. Key factors that are driving the gamma knife market growth include the rapid surge in the global incidence of neurological diseases such as brain tumors and epilepsy, rising adoption of the instruments in surgical centers, and product launch.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."